Appendix A: Cleaning Procedure

For the best results, it is recommended that this procedure be completed before the use of the Biotage® PrepXpert-8 each day and at the end of each extraction prior to proceeding with the next set of samples.

1. Ensure that an empty cleaning cartridge and sample bottle are installed onto each position on the automated extraction system.
2. Load and run the cleaning method outlined in the table below.
3. Remove the cleaning cartridges and sample bottles, disposing of the remaining solvent from the sample bottles.
4. Using methanol in a squeeze bottle, clean the adapters, sample bottle rinse heads, and the sip tubes.

Note: In situations where the previous sample was highly concentrated, the above cleaning procedure may need to be repeated multiple times. If there is concern regarding potential carryover contamination regardless of the cleaning procedure, a laboratory reagent blank should be run in that position to ensure its cleanliness

Table 5: Cleaning parameters

Operation	Amount (mL)	Input	Output	Flow (mL/min)
Rinse	5	MeOH	Sample rinse	60
Pump	2.5	MeOH	Sample	15
Pump	2.5	MeOH	Sample	15
Pump	5	Water	Sample	15
Pump	5	MeOH	Solvent waste	15
Pump	5	MeOH	Solvent waste	15
Dry	10 sec	Nitrogen	Solvent waste	-

Appendix B: MRM transitions

Table 6: MRM transitions for Agilent 6470 MS/MS

Compound name	Precursor ion	Product ion	Fragmentor (V)	Collision energy (V)	Cell acc (V)	Ret time (min)	Ret window	Polarity
6:2 FTS	427	406.8	125	24	5	5.97	1.2	Negative
6:2 FTS	427	80.9	125	40	5	5.97	1.2	Negative
8:2 diPAP	989	543	100	20	5	8.05	1.2	Negative
8:2 diPAP	989	97	100	20	5	8.05	1.2	Negative
8:2 FTS	527	506.8	170	28	5	6.71	1.2	Negative
8:2 FTS	527	80.9	170	40	5	6.71	1.2	Negative
8:2 FTUCA	457	393	100	28	5	6.50	1.2	Negative

© Biotage

8:2 FTUCA	457	343	100	28	5	6.50	1.2	Negative
9Cl-PF3ONS	530.9	350.9	145	28	5	6.58	1.2	Negative
9Cl-PF3ONS	530.9	83	145	32	5	6.58	1.2	Negative
ADONA	377	250.9	80	12	5	5.59	1.2	Negative
ADONA	377	85	80	36	5	5.59	1.2	Negative
C2-6:2FTS	429	81	125	24	5	6.01	1.2	Negative
C2-8:2FTS	529	81	170	28	5	6.75	1.2	Negative
C2-8:2FTUCA	459	394	100	28	5	6.54	1.2	Negative
C2-PFDA	515	470	81	4	5	6.72	1.2	Negative
C2-PFDoA	615	570	79	5	5	7.24	1.2	Negative
C2-PFHxA	315	270	70	8	5	4.89	1.2	Negative
C2-PFHxDA	815	770	100	20	5	7.95	1.2	Negative
C2-PFTeDA	715	670	79	5	5	7.65	1.2	Negative
C2-PFUnA	565	520	100	20	5	7.00	1.2	Negative
C3-HFPO-DA	287	169	64	4	5	5.64	1.2	Negative
C3-PFBS	302	80	100	45	5	4.32	1.2	Negative
C4-8:2diPAP	993	545	100	20	5	8.08	1.2	Negative
C4-PFBA	217	172	60	8	5	2.71	1.2	Negative
C4-PFHpA	367	322	72	0	5	5.56	1.2	Negative
C4-PFOA	417	372	80	8	5	5.99	1.2	Negative
C4-PFOS	503	80	100	50	5	6.39	1.2	Negative
C5-PFNA	468	423	66	4	5	6.40	1.2	Negative
C5-PFPeA	268	223	60	20	5	4.11	1.2	Negative
C8-FOSA	506	78	150	20	5	6.99	1.2	Negative
C8-PFOA	421	376	80	8	5	5.99	1.2	Negative
C8-PFOS	507	80	100	50	5	6.38	1.2	Negative
d3-N-MeFOSA	515	169	100	28	5	7.51	1.2	Negative
d3-N-MeFOSAA	573	419	100	20	5	6.90	1.2	Negative
d5-N-EtFOSA	531	169	100	32	5	7.68	1.2	Negative
d5-N-EtFOSAA	589	419	100	20	5	7.04	1.2	Negative
FOSA	498	169	100	38	5	6.95	1.2	Negative
FOSA	498	78	150	38	5	6.95	1.2	Negative
HFPO-DA	285	184.9	50	16	5	5.10	1.2	Negative
HFPO-DA	285	168.9	50	4	5	5.10	1.2	Negative
N-EtFOSA	526	219	100	32	5	7.66	1.2	Negative
N-EtFOSA	526	169	100	28	5	7.66	1.2	Negative
N-EtFOSAA	584	526	100	20	5	7.02	1.2	Negative
N-EtFOSAA	584	419	100	20	5	7.02	1.2	Negative
N-MeFOSA	512	219	100	28	5	7.49	1.2	Negative
N-MeFOSA	512	169	100	28	5	7.49	1.2	Negative
N-MeFOSAA	570	512	100	20	5	6.87	1.2	Negative
N-MeFOSAA	570	419	100	20	5	6.87	1.2	Negative
O2-PFHxS	403	84	100	49	5	5.55	1.2	Negative
PFBA	213	168.9	60	8	5	2.71	1.2	Negative
PFBS	298.9	98.9	100	29	5	4.26	1.2	Negative
PFBS	298.9	80	100	45	5	4.26	1.2	Negative
PFDA	513	469	81	4	5	6.72	1.2	Negative

© Biotage

PFDA	513	218.7	100	16	5	6.72	1.2	Negative
PFDoA	613	569	79	5	5	7.24	1.2	Negative
PFDoA	613	268.7	100	20	5	7.24	1.2	Negative
PFDS	599	99	100	40	5	6.98	1.2	Negative
PFDS	599	80	100	40	5	6.98	1.2	Negative
PFHpA	362.9	319	72	0	5	5.51	1.2	Negative
PFHpA	362.9	169	72	12	5	5.51	1.2	Negative
PFHpS	448.9	98.7	100	44	5	6.00	1.2	Negative
PFHpS	448.9	79.7	100	52	5	6.00	1.2	Negative
PFHxA	313	268.9	70	8	5	4.89	1.2	Negative
PFHxA	313	119	70	18	5	4.89	1.2	Negative
PFHxDA	813	769	79	5	5	7.92	1.2	Negative
PFHxDA	813	369	100	20	5	7.92	1.2	Negative
PFHxS	398.9	99	100	45	5	5.55	1.2	Negative
PFHxS	398.9	80	100	49	5	5.55	1.2	Negative
PFNA	463	419	66	4	5	6.39	1.2	Negative
PFNA	463	219	66	17	5	6.39	1.2	Negative
PFOA	413	369	69	4	5	5.99	1.2	Negative
PFOA	413	169	69	12	5	5.99	1.2	Negative
PFOcDA	913	869	79	5	5	8.15	1.2	Negative
PFOcDA	913	369	100	20	5	8.15	1.2	Negative
PFOS	498.9	99	100	50	5	6.38	1.2	Negative
PFOS	498.9	80	100	50	5	6.38	1.2	Negative
PFPeA	263	218.9	60	8	5	4.05	1.2	Negative
PFTeDA	713	669	79	5	5	7.62	1.2	Negative
PFTeDA	713	369	100	20	5	7.62	1.2	Negative
PFTrDA	663	619	79	5	5	7.45	1.2	Negative
PFTrDA	663	269	100	20	5	7.45	1.2	Negative
PFUnA	563	519	73	5	5	7.00	1.2	Negative
PFUnA	563	269	100	20	5	7.00	1.2	Negative

Appendix C: Calibration curves

Calibration curves for the target analytes in Table 1, covering a concentration range of 0.2-20 ppt.

PFBA



© Biotage

PFPeA



PFBS



PFHxA



© Biotage

HFPO-DA



PFHpA



PFHxS



© Biotage

ADONA



PFHpS



6:2 FTS



© Biotage

PFNA



8:2 FTUCA



PFDA



© Biotage

9Cl-PF3ONS



8:2 FTS



N-MeFOSAA



© Biotage

FOSA



PFDS



PFUnA



© Biotage

N-EtFOSAA



PFDoA



PFTrDA



© Biotage

N-MeFOSA



N-EtFOSA



PFTeDA



© Biotage

PFHxDA



8:2 diPAP



PFOcDA



© Biotage

Appendix D: MRL and DL data

Table 7: MRL and DL recoveries (2 ng/L, n=8).

	Conc.	1	2	3	4	5	6	7	8	$\bar{x}$	$\bar{x}$	s	CV	DL
	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(ng/L)	(%)	(ng/L)	(%)	(ng/L)
PFBA*	1.774	1.66	1.58	1.62	1.70	1.67	1.68	1.67	1.69	1.66	93	0.04	2.39	0.12
PFPeA	2.000	1.85	1.81	1.81	1.95	1.84	1.85	1.86	1.89	1.86	93	0.05	2.49	0.14
PFBS	2.000	1.92	1.83	1.78	1.96	1.86	1.85	1.86	1.85	1.86	93	0.06	3.01	0.17
PFHxA	2.000	1.80	1.77	1.77	1.94	1.83	1.85	1.87	1.89	1.84	92	0.06	3.20	0.18
HFPO-DA (GenX)	2.000	1.77	1.69	1.91	2.10	1.95	1.88	2.16	1.99	1.93	97	0.16	8.04	0.47
PFHpA	2.000	1.79	1.78	1.77	1.81	1.80	1.88	1.81	1.91	1.82	91	0.05	2.74	0.15
PFHxS*	1.896	1.91	1.76	1.74	1.91	1.90	1.74	1.82	1.84	1.83	96	0.08	4.17	0.23
ADONA*	1.890	1.68	1.66	1.69	1.75	1.71	1.70	1.77	1.78	1.72	91	0.04	2.55	0.13
PFHpS*	1.906	1.83	1.79	1.85	1.77	1.79	1.79	2.02	1.71	1.82	95	0.09	4.99	0.27
6:2 FTS*	1.902	2.29	2.19	2.13	2.20	2.09	2.23	2.20	1.95	2.16	114	0.11	4.86	0.31
PFOA	2.000	1.87	1.81	1.74	1.91	1.90	1.88	1.89	1.92	1.86	93	0.06	3.24	0.18
PFOS*	1.916	1.86	1.73	1.89	1.92	1.84	1.93	1.79	1.69	1.83	96	0.09	4.84	0.27
PFNA	2.000	1.69	1.75	1.77	1.84	1.92	1.82	1.77	1.73	1.79	89	0.07	4.04	0.22
8:2 FTUCA	2.000	1.71	1.57	1.70	1.82	1.84	1.87	1.70	1.81	1.75	88	0.10	5.79	0.30
PFDA	2.000	1.80	1.59	1.71	1.76	1.73	1.77	1.66	1.75	1.72	86	0.07	4.09	0.21
9Cl-PF3ONS*	1.866	1.64	1.54	1.73	1.75	1.68	1.60	1.60	1.66	1.65	88	0.07	4.27	0.21
8:2 FTS*	1.920	2.11	2.00	2.01	1.97	2.20	2.10	1.98	2.03	2.05	107	0.08	3.83	0.24
N-MeFOSAA	2.000	1.66	1.64	1.78	1.78	1.99	1.88	1.70	1.76	1.77	89	0.12	6.56	0.35
FOSA	2.000	1.88	1.70	1.64	1.92	1.91	1.89	1.79	1.88	1.83	91	0.10	5.67	0.31
PFDS	2.000	1.94	1.83	1.83	2.15	1.93	1.97	1.90	1.78	1.92	96	0.11	5.99	0.34
PFUnA	2.000	1.76	1.84	1.77	1.92	1.70	1.85	1.78	1.92	1.82	91	0.08	4.40	0.24
N-EtFOSAA	2.000	1.77	1.97	1.92	1.97	1.96	1.99	1.90	2.04	1.94	97	0.08	4.17	0.24
PFDoA	2.000	1.77	1.95	1.85	1.87	2.05	1.86	1.86	1.94	1.89	95	0.08	4.33	0.25
PFTrDA	2.000	1.67	1.80	1.87	1.85	1.94	1.70	1.87	1.96	1.83	92	0.11	5.85	0.32
N-MeFOSA	2.000	1.36	1.17		1.58	1.41	1.53	1.48	1.27	1.40	70	0.15	10.40	0.46
N-EtFOSA	2.000	1.38	1.08		1.33	1.37	1.60	1.36	1.09	1.32	66	0.18	13.65	0.57
PFTeDA	2.000	1.85	1.83	1.88	2.04	2.07	1.79	2.02	2.03	1.94	97	0.11	5.76	0.33
PFHxDA	2.000	1.99	1.80	1.70	1.83	1.82	1.93	1.69	2.01	1.85	92	0.12	6.64	0.37
8:2 diPAP*	1.956	1.85	1.60	1.39	1.70	1.54	1.65	1.58	1.87	1.65	84	0.16	9.62	0.48
PFOcDA	2.000	1.93	1.77	1.83	1.79	1.90	1.82	1.77	1.98	1.85	92	0.08	4.21	0.23

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.

© Biotage

Appendix E: Demonstration of precision and accuracy

Table 8: Results of IDP and IDA (10 ng/L. n=4).

	Conc.	1	2	3	4	$\bar{x}$	CV
	(ng/L)	(%)	(%)	(%)	(%)	(%)	(%)
PFBA*	8.87	102	101	102	101	101	0.85
PFPeA	10.00	100	100	101	101	101	0.82
PFBS	10.00	100	100	99	100	100	0.80
PFHxA	10.00	101	101	101	100	101	0.57
HFPO-DA (GenX)	10.00	95	98	101	100	99	2.56
PFHpA	10.00	101	97	107	105	102	4.16
PFHxS*	9.48	104	104	104	104	104	0.09
ADONA*	9.45	96	99	101	100	99	1.84
PFHpS*	9.53	104	106	101	100	103	2.67
6:2 FTS*	9.51	128	116	124	115	121	5.39
PFOA	10.00	104	103	104	100	103	2.04
PFOS*	9.58	101	101	101	100	101	0.45
PFNA	10.00	104	100	100	96	100	3.17
8:2 FTUCA	10.00	97	95	98	95	96	1.75
PFDA	10.00	98	98	97	95	97	1.51
9Cl-PF3ONS*	9.33	101	97	96	93	97	3.65
8:2 FTS*	9.60	115	113	116	118	116	1.74
N-MeFOSAA	10.00	91	91	96	94	93	2.85
FOSA	10.00	92	99	97	94	96	3.20
PFDS	10.00	94	90	99	90	93	4.62
PFUnA	10.00	99	95	97	102	98	2.76
N-EtFOSAA	10.00	93	104	98	98	98	4.43
PFDoA	10.00	100	101	104	106	103	2.37
PFTrDA	10.00	96	102	102	100	100	3.17
N-MeFOSA	10.00	62	53	64	50	57	11.74
N-EtFOSA	10.00	59	50	61	49	55	10.95
PFTeDA	10.00	105	120	105	110	110	6.15
PFHxDA	10.00	93	89	94	98	93	3.78
8:2 diPAP*	9.78	86	83	100	96	91	8.83
PFOcDA	10.00	102	101	99	100	100	1.26

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.

© Biotage

Appendix F: PFAS background study

Table 9: Demonstration of low PFAS background contribution from TurboVap® LV and EVOLUTE® PFAS cartridges.

	TurboVap® LV blanks				WAX column blanks			
	1	2	3	4	1	2	3	4
PFBA*	N.D.	N.D.	N.D.	N.D.	0.13	0.11	0.12	0.13
PFPeA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFBS	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFHxA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
HFPO-DA (GenX)	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFHpA	N.D.	N.D.	0.02	N.D.	N.D.	N.D.	N.D.	N.D.
PFHxS*	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
ADONA*	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFHpS*	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
6:2 FTS*	N.D.	N.D.	N.D.	N.D.	0.03	0.06	0.05	0.05
PFOA	N.D.	N.D.	N.D.	N.D.	0.06	0.04	0.03	0.05
PFOS*	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFNA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
8:2 FTUCA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFDA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
9Cl-PF3ONS*	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
8:2 FTS*	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
N-MeFOSAA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
FOSA	N.D.	N.D.	0.01	N.D.	N.D.	0.02	0.01	0.01
PFDS	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFUnA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
N-EtFOSAA	0.01	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFDoA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFTrDA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
N-MeFOSA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
N-EtFOSA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFTeDA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFHxDA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
8:2 diPAP*	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFOcDA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.

© Biotage

Table 10: Demonstration of low PFAS background contribution from the Biotage® PrepXpert-8.

	Biotage® PrepXpert-8 blanks							
	1	2	3	4	5	6	7	8
PFBA*	0.01	0.02	0.00	0.03	0.04	0.07	0.06	0.06
PFPeA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFBS	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	0.05	0.03
PFHxA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
HFPO-DA (GenX)	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFHpA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFHxS*	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
ADONA*	N.D.	0.01	N.D.	N.D.	N.D.	0.01	0.01	0.01
PFHpS*	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
6:2 FTS*	0.03	0.03	0.02	0.02	0.06	0.05	0.02	0.08
PFOA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFOS*	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFNA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
8:2 FTUCA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFDA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
9Cl-PF3ONS*	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
8:2 FTS*	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
N-MeFOSAA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
FOSA	0.01	0.03	0.01	0.02	0.01	0.03	0.01	N.D.
PFDS	N.D.	N.D.	0.03	N.D.	N.D.	N.D.	N.D.	N.D.
PFUnA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
N-EtFOSAA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFDoA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFTrDA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	0.01
N-MeFOSA	N.D.	N.D.	0.04	0.00	0.09	0.04	N.D.	N.D.
N-EtFOSA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFTeDA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFHxDA	0.02	0.03	0.03	0.00	0.05	0.04	N.D.	0.05
8:2 diPAP*	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFOcDA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.

© Biotage

Table 11: Demonstration of low PFAS background in reagent water blanks (RWB) and results of carry-over study of RWB after the running of high PFAS contamination through the system and system cleaning.

	Reagent water blanks				Carry-over blanks			
	1	2	3	4	1	2	3	4
PFBA*	0.18	0.04	0.02	0.02	N.D.	N.D.	N.D.	N.D.
PFPeA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFBS	N.D.	N.D.	N.D.	N.D.	0.01	0.01	N.D.	0.01
PFHxA	0.01	0.01	0.01	0.01	N.D.	N.D.	N.D.	N.D.
HFPO-DA (GenX)	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFHpA	0.01	0.01	0.02	N.D.	N.D.	N.D.	N.D.	N.D.
PFHxS*	0.02	0.03	0.03	0.04	0.00	N.D.	N.D.	N.D.
ADONA*	N.D.	0.01	0.01	N.D.	N.D.	N.D.	N.D.	N.D.
PFHpS*	N.D.	N.D.	0.10	N.D.	N.D.	N.D.	N.D.	N.D.
6:2 FTS*	0.01	0.01	0.04	N.D.	0.01	0.01	0.01	0.01
PFOA	0.01	0.01	0.03	0.02	0.05	N.D.	0.08	0.05
PFOS*	0.01	N.D.	0.08	N.D.	N.D.	N.D.	N.D.	N.D.
PFNA	0.01	N.D.	0.06	N.D.	N.D.	N.D.	N.D.	N.D.
8:2 FTUCA	N.D.	N.D.	N.D.	N.D.	0.08	0.08	0.04	0.05
PFDA	0.01	0.01	0.07	N.D.	0.05	N.D.	N.D.	N.D.
9Cl-PF3ONS*	0.01	N.D.	0.10	N.D.	0.04	0.01	N.D.	N.D.
8:2 FTS*	N.D.	N.D.	0.10	N.D.	N.D.	N.D.	N.D.	N.D.
N-MeFOSAA	N.D.	N.D.	N.D.	N.D.	0.07	0.09	0.03	0.03
FOSA	N.D.	0.01	N.D.	N.D.	0.03	0.04	0.02	0.02
PFDS	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFUnA	N.D.	N.D.	0.09	N.D.	N.D.	N.D.	N.D.	N.D.
N-EtFOSAA	N.D.	N.D.	N.D.	N.D.	0.03	0.04	0.04	0.03
PFDoA	N.D.	N.D.	0.08	N.D.	0.03	0.02	0.01	0.01
PFTrDA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
N-MeFOSA	N.D.	N.D.	N.D.	N.D.	0.03	0.03	0.02	0.03
N-EtFOSA	N.D.	N.D.	N.D.	N.D.	0.03	0.03	0.03	0.03
PFTeDA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFHxDA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
8:2 diPAP*	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
PFOcDA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.

© Biotage